Atopic dermatitis

Langan, Sinéad; Irvine, Alan D.; Weidinger, Stephan

doi:10.1016/s0140-6736(20)31286-1

Cited by 1,095 publications

(1,306 citation statements)

References 216 publications

Supporting

Mentioning

1,073

Contrasting

Unclassified

Order By: Relevance

“…Skin barrier dysfunction and immune disorders are the primary pathological conditions. These factors lead to inflammation, primarily type 2 5 . Physicians who treat AD should be able to handle cases affecting a wide range of age groups, and need to be familiar with management of exacerbations.…”

Section: Introductionmentioning

confidence: 99%

Current treatments for atopic dermatitis in Japan

Miyano

Tsunemi

2020

The Journal of Dermatology

View full text Add to dashboard Cite

The goal of a treatment regimen for atopic dermatitis is to reach and maintain a state where the patient exhibits mild symptoms or an absence of symptoms, and the patient should not experience disturbance during daily activities. The basis of a treatment regimen for atopic dermatitis is topical therapy, and currently there exist topical corticosteroids, tacrolimus and delgocitinib. Using these, proactive therapy is performed as maintenance therapy after remission induction therapy. However, in cases of moderate to severe atopic dermatitis, topical drugs alone cannot induce remission and systemic therapies such as cyclosporin, ultraviolet therapy, and dupilumab should be used in combination. In particular, dupilumab has many advantages such as high efficacy, relatively few adverse reactions, and ease of use in elderly patients with severe atopic dermatitis. In this review, we present a treatment algorithm for atopic dermatitis that emphasizes the importance of maintaining remission after induction of remission, and summarizes the characteristics of current medication therapy for atopic dermatitis in Japan.

show abstract

Section: Introductionmentioning

confidence: 99%

Current treatments for atopic dermatitis in Japan

Miyano

Tsunemi

2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Also, circulating memory CLA + T cells specific for disease relevant antigens/allergens have reported, for example, S. pyogenes in PSO (22) or house dust mite and Staphylococcus aureus enterotoxin B in AD (4). Despite the functional relevance of memory CLA + T cells has been better described in PSO and AD (4,22,49); their potential role in other T cell-mediated skin conditions is still to be fully investigated. Various approaches that involve minimal manipulation of those cells are providing immunological information that relates to clinic in a translational way.…”

Section: Discussionmentioning

confidence: 99%

The Translational Relevance of Human Circulating Memory Cutaneous Lymphocyte-Associated Antigen Positive T Cells in Inflammatory Skin Disorders

et al. 2021

View full text Add to dashboard Cite

Circulating memory T cells are heterogeneous in their tissue tropism. The skin-seeking T cell subset expresses the cutaneous lymphocyte-associated antigen (CLA) on their surface. CLA+ memory T cells not only migrate from blood to skin but also recirculate between blood and skin. Studying CLA+ memory T cells in cutaneous diseases has allowed a better understanding of immune-inflammatory mechanisms that take place. The analysis of the phenotypical features of these cells, their antigen specificity, cytokine production profile, and changes in relationship to clinical status and therapies among other characteristics have led to the concept that they constitute peripheral cellular biomarkers in T cell-mediated cutaneous conditions. CLA+ memory T cells are of relevance in the pathogenesis of several cutaneous diseases, such as psoriasis (PSO), atopic dermatitis, vitiligo, and drug-induced allergic reactions, to name a few. The interaction of circulating CLA+ T cells with skin-resident cells has been investigated in different ex vivo coculture models made out of clinical samples. Interestingly, microbes that are present in the skin or related with human skin diseases are preferentially recognized by CLA+ T cells. Thus, the interaction of Streptococcus pyogenes with CLA+ T cells in PSO is providing novel concepts that help to understand disease immunopathogenesis. The goal of this review is to present latest results in the field of CLA+ T cells in T cell-mediated inflammatory skin diseases and their translational relevance for human immunodermatology.

show abstract

“…It is known that Th2-type cytokines (IL-4, IL-5, and IL-13) and epithelial-derived innate type-2 cytokines (TSLP) increased in skin lesions of acute stage of AD (DeVore et al, 2020;Edslev et al, 2020;Langan et al, 2020). TSLP is crucial for regulating the downstream IL-4/IL-13 and Th2 differentiation.…”

Section: Discussionmentioning

confidence: 99%

“…Atopic dermatitis is a common inflammatory skin disorder. The prevalence of AD is approximately 30% in children and 10% in adults (Bin et al, 2014;Langan et al, 2020). AD is characterized by eczematous lesions with severe itching and often associated with allergic rhino-conjunctivitis, food allergy and asthma (Alduraywish et al, 2016;Matsumoto et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Interferon-Lambda 1 Inhibits Staphylococcus aureus Colonization in Human Primary Keratinocytes

Zhao

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common inflammatory skin disease. Staphylococcus aureus (S. aureus) colonization in skin lesions occurs in approximately 70% of AD patients. It has been found that IFN-λ1 can inhibit the colonization of S. aureus in normal human nasal mucosa. IFN-λ1 can increase IL-28RA in infected human keratinocytes. In this study, we found that IFN-λ1 can increase mRNA expression of FLG and antimicrobial peptides (AMPs) and inhibit TSLP mRNA expression in infected human keratinocytes. IFN-λ1 can increase intracellular ROS level, decrease STAT1 phosphorylation, and inhibit the colonization of S. aureus in human primary keratinocytes. These effects were attenuated by knocking-down IL-28R and NADPH oxidase inhibitor, suggesting that this function was mediated by JAK-STAT1 signaling pathway. These results suggest that IFN-λ1 might have an inhibitory effect on S. aureus colonization in AD lesions. Our findings might have potential value in the treatment for AD.

show abstract

Atopic dermatitis

Cited by 1,095 publications

References 216 publications

Current treatments for atopic dermatitis in Japan

Current treatments for atopic dermatitis in Japan

The Translational Relevance of Human Circulating Memory Cutaneous Lymphocyte-Associated Antigen Positive T Cells in Inflammatory Skin Disorders

Interferon-Lambda 1 Inhibits Staphylococcus aureus Colonization in Human Primary Keratinocytes

Contact Info

Product

Resources

About